Department of Internal Medicine, Sultan 2. Abdulhamid Han Training and Research Hospital, İstanbul, Turkey.
Department of Gastroenterology, Sultan 2. Abdulhamid Han Training and Research Hospital, İstanbul, Turkey.
Turk J Gastroenterol. 2022 Nov;33(11):918-924. doi: 10.5152/tjg.2022.21456.
The aim of the study was to evaluate whether a new and successful treatment opportunity can be provided in acute pancreatitis and may prevent symptomatic treatments and show its effect through etiopathogenesis. Therefore, we want to investigate the efficacy of golimumab in an experimental rat model of cerulein-induced acute pancreatitis.
A total of 35 rats, including 7 rats in each group, were distributed into 5 groups (sham, acute pancreatitis, placebo, acute pancreatitis+golimumab 5 mg/kg, and acute pancreatitis+golimumab 10 mg/kg). An experimental cerulein-induced acute pancreatitis model was accomplished by intraperitoneal cerulein injections. After sacrification, rat blood samples were collected for amylase, IL-6, and IL-1beta measurements. Histopathological analysis of the pancreas was performed with Tunel and hematoxylin and eosin staining.
Amylase, IL-6, and IL-1beta levels were found to be increased in the acute pancreatitis group. IL-1beta, amylase, IL-6 levels, and pancreatic inflammation were all significantly decreased in golimumab groups (P < .01). Moreover, in both golimumab groups, golimumab treatment significantly reduced apoptosis in pancreatic tissues (P < .05). Golimumab treatment was found to significantly reduce edema formation, inflammation, vacuolization, and fat necrosis of pancreatic tissues (P < .05).
Firstly in the literature, we investigated the efficacy of golimumab in the experimental acute pancreatitis model. In the light of our findings, it could be suggested that golimumab may be an effective and safe therapeutic option in the treatment of patients with acute pancreatitis.
本研究旨在评估一种新的、成功的治疗方法是否可以应用于急性胰腺炎，并通过病因发病机制来预防症状性治疗及显示其疗效。因此，我们想在胰酶诱导的急性胰腺炎大鼠模型中研究戈利木单抗的疗效。
总共 35 只大鼠，每组 7 只，分为 5 组（假手术组、急性胰腺炎组、安慰剂组、急性胰腺炎+戈利木单抗 5mg/kg 组和急性胰腺炎+戈利木单抗 10mg/kg 组）。通过腹腔内注射胰酶建立实验性急性胰腺炎模型。处死大鼠后，采集大鼠血样，检测淀粉酶、IL-6 和 IL-1β。胰腺组织行 TUNEL 和苏木精-伊红染色进行组织病理学分析。
在急性胰腺炎组中发现淀粉酶、IL-6 和 IL-1β水平升高。在戈利木单抗组中，IL-1β、淀粉酶、IL-6 水平和胰腺炎症均显著降低（P＜0.01）。此外，在戈利木单抗组中，戈利木单抗治疗可显著减少胰腺组织中的细胞凋亡（P＜0.05）。戈利木单抗治疗可显著减少胰腺组织水肿、炎症、空泡化和脂肪坏死（P＜0.05）。
我们首次在文献中研究了戈利木单抗在实验性急性胰腺炎模型中的疗效。根据我们的发现，可以认为戈利木单抗可能是治疗急性胰腺炎患者的一种有效且安全的治疗选择。
